Management Team
Klotho Neuroscience’s leadership team is made up of individuals who are dedicated to upholding the company’s core principles of cutting-edge technology, quality, and integrity. We will produce and sell products with the highest quality we expect for ourselves, our children and our family and friends. This was the key driving principle for the formation of the company and its ongoing operations.
The team is comprised of individuals with the technical, biopharmaceutical manufacturing, gene therapy, cell therapy, clinical, regulatory, and business expertise that is necessary for innovation and success. The combination of this experience will contribute to the development of a diverse range of life-saving medicines.
Our staff includes personnel and advisors in the U.S. and Europe who have extensive experience in the “branded” pharmaceutical and biotechnology commercial processes for making and selling biologic-based drugs. The Company will exploit its technical and commercial expertise to develop and obtain approval to launch, market and sell our own branded product lines, and/or to develop partnerships with other large pharmaceutical corporations to market and sell our products.
Dr. Joseph SinkuleFounder, Chief Executive Officer (CEO), Director and Chairman of the Board
Dr. Sinkule is the company’s Chief Executive Officer (CEO), Founder, and the Chairman of the Board of Directors. He has over 40 years of drug, biologic, and medical device R&D and commercialization experience. This serial entrepreneur is the founder and driving force behind the Company, its growing product portfolio, and its financing strategies. He has personally managed over 8 drug and biotech products successfully through FDA approval to market, 5 medical devices and 8 in vitro diagnostics. He has hired and managed both small and large teams of experienced people in pharma and biotech organizations, and managed contract research organizations (“CROs”) and contract development and manufacturing companies (“CDMOs”), working for large and small clients. After serving in academics and then in industry, Dr. Sinkule has evolved into a successful businessman and entrepreneur. He serves on the Board of two companies, and routinely consults for venture capitalist firms, investment banks, as well as both large and early-stage pharmaceutical and biotech companies.
Mr. Jeffrey LeBlancChief Financial Officer
Mr. LeBlanc has over 20 years of experience in managing financial operations, investing, advising Fortune 500 companies, and launching new ventures. He is the co-founder of Winvest Acquisition Corp. (Ticker: WINV), a special purpose acquisition company. Prior to Winvest, Mr. LeBlanc launched Out of Print, a direct-to-consumer merchandise platform that was acquired by Penguin Random House in 2017. He previously served in investment roles at Greenlight Capital and GE Capital, and started his career at McKinsey and Co. Mr. LeBlanc previously served on the Boards of Riot New Media Group and Books For Africa. He received an MBA from Harvard Business School and a BS in Chemical Engineering from MIT.
Bo Møller StensgaardPresident
Bo is a seasoned executive with over 20 years in mineral exploration and natural resource development across Europe and the Arctic, starting in Greenland geology in 1998. Holding a PhD in economic geology and former Senior Research Scientist at the Geological Survey of Danmark and Greenland, he has led listed and private resource companies, advancing projects from early exploration to exploitation through technical studies, environmental/social impact assessments, permitting, and stakeholder engagement. His expertise includes listed-company leadership, international investor relations, building expert teams, and leveraging extensive networks in business, academia, politics, and the European raw materials ecosystem – gained partly from his senior advisory role at EIT RawMaterials advising on EU policy and funding. This positions him as a strong leader for Greenland Mines Corp, providing credible access to North American and European capital markets and strategic partners.
Dr. Miguel Chillón RodriguezChief Scientific Officer and Consultant
Professor Dr. Chillon is the inventor of the α-Klotho patents and technology know how. He has over 25 years of research experience in several key areas of α-klotho and adeno-associated virus (“AAV”) packaging and gene delivery. Miguel has several associates that work with him to expedite development and further the intellectual properties and scientific publications. He leads the research group on Gene therapy for CNS diseases at Universitat Autonoma De Barcelona and Institucio Catalana De Recerca I Estudis Avancats. Miguel is also the Director of the Viral Vector Production Unit at Vall d’Hebrón Hospital, and serves Chair of the ATMP Platform of European Infrastructure for Translational Medicine
Dr. Shalom HirshmanMedical Advisor and Director
Dr. Shalom Hirschman, M.D. is a preeminent research physician, a clinical medical expert, and entrepreneur in infectious diseases, oncology, and cancer supportive care. He is a key consulting advisor to the Company. As a young man, he served as an intern and resident in medicine at the Massachusetts General Hospital and Harvard Medical School, and then went on to a career in molecular biology and virology research at the National Institute of Health (NIH). During his career in medical research, he interacted closely with several Nobel Prize winners including Drs. Berson and Yalow (Nobel Prize for development of radioimmunoassays). He was recruited to The Mount Sinai School of Medicine and The Mount Sinai Hospital in New York City as Head of the Department of Infectious Diseases, and eventually he also became Vice-Chairman and Chairman of the Department of Medicine at Mount Sinai, where he remained for three decades. He still is asked to consult on difficult diagnostic dilemmas like the recent COVID-19 pandemic.